摘要
目的：观察胶体酒石酸 对功能性结肠疾病的疗效及安全性。方法：１４８例确诊为功能性结肠疾病病人随机分为３组。胶体酒石酸 组６２例，男性 ２３例，女性 ３９例，年龄（４０± ｓ ８） ａ，给胶体酒石酸 １６５ ｍｇ，ｐｏ， ｑｉｄ × ４ ｗｋ。对照组分 ２组：双歧杆菌组 ４６例，男性 １７例，女性 ２９例，年龄（４２ ±５）ａ，给双歧杆菌活菌制剂７００ ｍｇ，ｐｏ，ｂｉｄ × ４ ｗｋ；西沙必利组４０例，男性１５例，女性２５例，年龄（３８± ７） ａ，给西沙比利 ５ ｍｇ，ｐｏ， ｔｉｄ × ４ ｗｋ。结果：胶体酒石酸 治疗前后症状评分差值与总有效率分别为（３０７± ６）分和 ８９％；与双歧杆菌组（１６３± ５）分和７０％；与西沙比利组（１８９ ± ８）分和６４％比较（Ｐ＜０． ０１， Ｐ＜ ０． ０５）。结论：胶体酒石酸 对功能性结肠疾病有良好疗效且安全，不良反应少。
AIM: To observe the curative effect and the safety of collodal bismuth tartrate in treating functional colonic diseases. METHODS: Functional collonis diseases 148 patients were randomly separated into three groups. Sixty-two patients of collodal bismuth tartrate group (M 23, F 39, age 40 a+- s & a) were given collodal bismuth tartrate 165 mg, po, gid X 4 wk. Controlled groups were separated two groups; Forty-six patients of Bifidobacteria group (M 17, F 29; age 42 a+- 5 a) were given viable bifidobacteria agent 700 mg, po, bid X 4 wk; Forty Patients of cisapride group (M 15, F 25, age 38 a +- 7 a) were given cisapride 5 mg, po, tid X 4 wk. RESULTS: After treatment the difference of scores and total effective rate of collodal bismuth tartrate group was 307 +- 6 and 89%, respectively; Bifidobacteria group was 163 +- 5 and 70%, respectively; cisapride group was 189 +- 8 and 64%, respeCtively; curative effect of collacol bismuth tartrate group and controlled group have obviously differences (P < 0. 05 ). CONCLUSION: Collodal bismuth tartrate in treating functions colnic disease has fine curative effect and safety, and mild adverse reactions.
出处
《中国新药与临床杂志》
CSCD
北大核心
2000年第2期119-121,共3页
Chinese Journal of New Drugs and Clinical Remedies
关键词
功能性结肠疾病
药物疗法
胶体酒石酸铋
functional colonic diseases
collodal bismuth tartrate
Bifidobacterium
cisapride
